These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 20135697)

  • 1. siRNA applications in nanomedicine.
    Tokatlian T; Segura T
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(3):305-15. PubMed ID: 20135697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
    Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine based approaches for the delivery of siRNA in cancer.
    Ozpolat B; Sood AK; Lopez-Berestein G
    J Intern Med; 2010 Jan; 267(1):44-53. PubMed ID: 20059643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical and structural modifications of RNAi therapeutics.
    Ku SH; Jo SD; Lee YK; Kim K; Kim SH
    Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
    De Paula D; Bentley MV; Mahato RI
    RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.
    Mainini F; Eccles MR
    Molecules; 2020 Jun; 25(11):. PubMed ID: 32532030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery systems of small interfering RNA by systemic administration.
    Kawakami S; Hashida M
    Drug Metab Pharmacokinet; 2007 Jun; 22(3):142-51. PubMed ID: 17603214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioengineered nanoparticles for siRNA delivery.
    Kozielski KL; Tzeng SY; Green JJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2013; 5(5):449-68. PubMed ID: 23821336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemistry and formulations for siRNA therapeutics.
    Gallas A; Alexander C; Davies MC; Puri S; Allen S
    Chem Soc Rev; 2013 Oct; 42(20):7983-97. PubMed ID: 23857524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interfering cancer with polymeric siRNA nanomedicines.
    Tiram G; Scomparin A; Ofek P; Satchi-Fainaro R
    J Biomed Nanotechnol; 2014 Jan; 10(1):50-66. PubMed ID: 24724498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivering siRNA with Dendrimers: In Vivo Applications.
    Leiro V; Santos SD; Pego AP
    Curr Gene Ther; 2017; 17(2):105-119. PubMed ID: 28494741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of nanocarriers for the delivery of small interfering RNA.
    Kesharwani P; Gajbhiye V; Jain NK
    Biomaterials; 2012 Oct; 33(29):7138-50. PubMed ID: 22796160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in siRNA delivery for cancer therapy using smart nanocarriers.
    Zhang P; An K; Duan X; Xu H; Li F; Xu F
    Drug Discov Today; 2018 Apr; 23(4):900-911. PubMed ID: 29373841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.